71633-86-8

Upstream product

• 619-57-8 p-hydroxybenzamide 
• 74-96-4 ethyl bromide 
• 25984-63-8 4-hydroxythiobenzamide 

Downstream Products

• 80269-20-1 [2-(4-Ethoxy-phenyl)-4-methyl-thiazol-5-yl]-oxo-acetaldehyde 
• 80269-38-1 2-[2-(4-Ethoxy-phenyl)-4-methyl-thiazol-5-yl]-quinoxaline 
• 80269-29-0 [2-(4-Ethoxy-phenyl)-4-methyl-thiazol-5-yl]-hydroxy-acetic acid 
• 80269-33-6 [2-(4-Ethoxy-phenyl)-4-methyl-thiazol-5-yl]-oxo-acetic acid 
• 58765-87-0 2-(4-ethoxy-phenyl)-4-methyl-thiazole-5-carboxylic acid 

Relevant academic research and scientific papers

Phenylthiazole antibiotics: A metabolism-guided approach to overcome short duration of action

Antibacterial resistance is a pressing global health challenge that necessitates the development of new therapeutic agents. Phenylthiazole antibacterial agents have been extensively studied, by our group, as a potential novel class of antibiotics to circumvent the scourge of antibacterial resistance. Previously, the phenylthiazole lead compound 1 was shown to possess potent activity against clinical isolates of methicillin- and vancomycin-resistant Staphylococcus aureus (MRSA and VRSA). The promising activity of this novel class of antibiotics is hampered by their short half-life due to rapid hepatic metabolism. In the present study, a metabolic methylene soft spot in the lead 1 was identified and replaced with an oxygen atom. The newly developed phenylthiazoles, with alkoxy side chains, demonstrate high metabolic stability (t1/2> 4 h), while maintaining their potent anti-MRSA activity. Furthermore, compound 5p demonstrated a selective advantage over vancomycin with its ability to kill intracellular MRSA.